CLINICAL TRIALS PROFILE FOR DOXYLAMINE SUCCINATE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for doxylamine succinate
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| OTC | NCT00796315 ↗ | Study Evaluating the Pharmacokinetics of Doxylamine Succinate in Children | Completed | Consumer Healthcare Products Association | Phase 1 | 2008-12-01 | The primary goal of this study is to characterize the pharmacokinetics of doxylamine succinate in children ages 2 to < 18 years. Once characterized, these pediatric pharmacokinetic data will be pooled with historical adult PK data from other studies to assess whether the existing Over-the-Counter (OTC)doses provide comparable systemic drug exposure as that associated with efficacy in adults. |
| OTC | NCT00796315 ↗ | Study Evaluating the Pharmacokinetics of Doxylamine Succinate in Children | Completed | Procter and Gamble | Phase 1 | 2008-12-01 | The primary goal of this study is to characterize the pharmacokinetics of doxylamine succinate in children ages 2 to < 18 years. Once characterized, these pediatric pharmacokinetic data will be pooled with historical adult PK data from other studies to assess whether the existing Over-the-Counter (OTC)doses provide comparable systemic drug exposure as that associated with efficacy in adults. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for doxylamine succinate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00293644 ↗ | Pre-emptive Treatment of Severe Nausea and Vomiting of Pregnancy | Completed | Duchesnay Inc. | Phase 3 | 2006-02-01 | The purpose of this study is to determine whether pre-emptive use of a delayed release combination of pyridoxine hydrochloride and doxylamine succinate (Diclectin®), before eruption of symptoms of Nausea and vomiting of pregnancy and hyperemesis gravidarum, will reduce the incidence of severe forms of this syndrome/HG. |
| NCT00293644 ↗ | Pre-emptive Treatment of Severe Nausea and Vomiting of Pregnancy | Completed | The Hospital for Sick Children | Phase 3 | 2006-02-01 | The purpose of this study is to determine whether pre-emptive use of a delayed release combination of pyridoxine hydrochloride and doxylamine succinate (Diclectin®), before eruption of symptoms of Nausea and vomiting of pregnancy and hyperemesis gravidarum, will reduce the incidence of severe forms of this syndrome/HG. |
| NCT00614445 ↗ | The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy | Completed | Premier Research Group plc | Phase 3 | 2008-01-01 | The purpose of this study is to determine whether Diclectin® (doxylamine succinate USP 10 mg and pyridoxine HCl 10 mg) is more effective at controlling the nausea and vomiting of pregnancy than a placebo. |
| NCT00614445 ↗ | The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy | Completed | Duchesnay Inc. | Phase 3 | 2008-01-01 | The purpose of this study is to determine whether Diclectin® (doxylamine succinate USP 10 mg and pyridoxine HCl 10 mg) is more effective at controlling the nausea and vomiting of pregnancy than a placebo. |
| NCT00796315 ↗ | Study Evaluating the Pharmacokinetics of Doxylamine Succinate in Children | Completed | Consumer Healthcare Products Association | Phase 1 | 2008-12-01 | The primary goal of this study is to characterize the pharmacokinetics of doxylamine succinate in children ages 2 to < 18 years. Once characterized, these pediatric pharmacokinetic data will be pooled with historical adult PK data from other studies to assess whether the existing Over-the-Counter (OTC)doses provide comparable systemic drug exposure as that associated with efficacy in adults. |
| NCT00796315 ↗ | Study Evaluating the Pharmacokinetics of Doxylamine Succinate in Children | Completed | Procter and Gamble | Phase 1 | 2008-12-01 | The primary goal of this study is to characterize the pharmacokinetics of doxylamine succinate in children ages 2 to < 18 years. Once characterized, these pediatric pharmacokinetic data will be pooled with historical adult PK data from other studies to assess whether the existing Over-the-Counter (OTC)doses provide comparable systemic drug exposure as that associated with efficacy in adults. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for doxylamine succinate
Condition Name
Clinical Trial Locations for doxylamine succinate
Trials by Country
Clinical Trial Progress for doxylamine succinate
Clinical Trial Phase
Clinical Trial Sponsors for doxylamine succinate
Sponsor Name
